It slowed the cancer but did not prove patients lived longer: the FDA says no to ivonescimab, and Akeso’s shares plunge
The US Food and Drug Administration has refused to approve ivonescimab, a Chinese-invented lung cancer drug that has drawn some of the world's biggest drugmakers into partnerships, for patients whose cancer has progressed after targeted EGFR therapy. Its US partner, Summit Therapeutics, says the regulator found that slowing the cancer was not enough without a statistically significant improvement in overall survival, and shares in the drug's inventor, Akeso, plunged in Hong Kong on Monday.
Three things to know
- The FDA issued a complete response letter, its formal refusal of an application in its current form, for ivonescimab with chemotherapy in advanced EGFR-mutated non-small cell lung cancer.
- The HARMONi trial met its goal of delaying cancer progression, but its main survival analysis showed only a positive trend, not a statistically significant result.
- The ruling covers only one use. The drug remains approved in China, and several large trials in first-line lung cancer and other cancers continue.
One of the most closely watched cancer drugs in the world has hit its first wall in the United States.
Summit Therapeutics said on 15 November, US time, that the FDA had issued a complete response letter for its application to sell ivonescimab, combined with platinum chemotherapy, to people with locally advanced or metastatic non-small cell lung cancer whose tumours carry an EGFR mutation and who have already been treated with an EGFR-targeted tablet.
According to Summit, the FDA determined that substantial evidence of effectiveness had not been established without a statistically significant improvement in overall survival, and that a benefit in progression-free survival alone did not support a positive balance of benefit and risk for approval.
On Monday, Akeso, the Hong Kong-listed company that invented the drug, told the exchange that unusual movements in its share price may have been caused by the regulatory announcement, and that it knew of no other reason. Its shares plunged.
Why is this drug such a big deal?
Ivonescimab is a bispecific antibody: one molecule built to hit two targets. It blocks PD-1, the immune checkpoint targeted by blockbuster drugs such as Keytruda, and VEGF, the signal tumours use to grow new blood vessels.
That combination made it one of the hottest assets in cancer medicine. Akeso, which calls the drug AK112, licensed rights in North America, Europe, Japan and other territories to Miami-based Summit, which calls it SMT112. Summit’s partners now include AstraZeneca, GSK and other drugmakers testing the drug in combination with their own medicines.
No PD-1 and VEGF bispecific has yet been approved in the United States, according to Summit, so this decision was a test of the whole class as well as one drug.
What did the trial actually show?
HARMONi was a global, randomised, double-blind phase 3 trial comparing ivonescimab plus chemotherapy with placebo plus chemotherapy, in patients whose cancer had progressed after a third-generation EGFR inhibitor. It had two primary goals: delaying progression and extending survival.
Summit says the drug met the first goal. On survival, the primary analysis showed a positive trend that did not reach statistical significance. Summit says longer follow-up of western patients showed a consistent benefit, with a hazard ratio of 0.76 across the full population, Asian patients and western patients, but that was a later analysis, not the trial’s pre-set test.
On safety, 7.3 per cent of patients stopped ivonescimab because of treatment-related side effects, against 5 per cent on placebo. Four patients on the ivonescimab regimen and five on chemotherapy alone died from treatment-related side effects, according to the company.
What does the FDA’s line mean for patients?
The ruling shows how the regulator is weighing cancer drugs that delay progression without clearly extending life. For patients in this group, whose cancer has outgrown targeted tablets, chemotherapy remains the main option in the US.
Summit’s co-chief executive Robert Duggan said the company was “disappointed for patients and their families”. He added that with “five positive Phase III studies between Summit and Akeso, nothing changes” in the company’s belief in the drug.
The drug is not approved in the United States or Europe, according to Summit, and US decisions often shape how quickly new cancer medicines reach other regulators, including in Australia.
Is the drug finished?
No. Ivonescimab was first approved in China in May 2024, and the US decision does not affect that. Summit is running phase 3 trials in first-line lung cancer, including HARMONi-3 with chemotherapy and HARMONi-7 as a single drug in patients with high PD-L1 levels, plus trials in bowel, bladder, kidney, head and neck and biliary cancers.
Summit has not announced whether it will resubmit this application.
What happens next
- Summit has not set out a timeline for resubmitting or appealing; any next step on this application will come from the company.
- Results from HARMONi-3 and HARMONi-7, in first-line lung cancer, are the bigger tests for the drug's future in the US and Europe.
- Akeso's share price in Hong Kong will be watched for how far investors mark down the drug's global prospects.
Sources
- VNN
VNN never names people who give us information in confidence. How we protect sources and tips.
That is the story in a minute. For the evidence, context and what happens next, switch to the full story.
Weather today
Monday 16 November
Perth
Warm under grey skies · 10% rain
27°16°
A warm, grey Monday for Perth; heavy showers soak Brisbane and Singapore, Paris stays wet and London wakes cold but bright.
- Sydney18°15°
- Melbourne14°9°
- Brisbane28°20°
- Adelaide19°10°
- Auckland21°15°
- Singapore28°25°
More cities (13)
- Tokyo18°13°
- Hong Kong26°20°
- Mumbai32°23°
- Dubai30°20°
- Nairobi24°16°
- Lagos31°26°
- Johannesburg27°15°
- London7°4°
- Paris11°10°
- New York10°4°
- Los Angeles20°16°
- Toronto9°4°
- Sao Paulo25°19°
Highs and lows in °C, local time.
Breaking now
Live deskDeveloping stories
Live deskMost read this week
For subscribers
Read every subscriber story in full, on any device. Premium reports are sold separately.
Secure payment · Cancel anytime · Subscribers sign in
Markets
Stocks
- Alphabet (GOOGL)Nasdaq295.77 USDdown -0.98%
- Amazon (AMZN)Nasdaq266.66 USDdown -0.29%
- Apple (AAPL)Nasdaq356.27 USDup +0.39%
- ASX 200ASX9,082.20down -0.71%
- Berkshire Hathaway (BRK.B)NYSE592.94 USDup +0.53%
- BHP Group (BHP)ASX58.86 AUDdown -1.26%
Currencies
- AUD/EURForex0.613500 EURdown -0.29%
- AUD/GBPForex0.511800 GBPdown -0.47%
- AUD/JPYForex107.8800 JPYdown -0.85%
- AUD/NZDForex1.224200 NZDdown -0.25%
- AUD/USDForex0.675900 USDdown -0.66%
- BTC/USDCrypto68,241.00 USDdown -4.59%
As at 14 Nov 2026, 5:52 am GMT+0800. Entered by VNN. Not financial advice.
For you
Follow the topics you care about and save stories with the bookmark. They gather here, on this device only.
Saved on this device only. Nothing is sent to VNN.
Help keep the lights on.
Independent news costs money to make and nothing to read. Chip in and keep it that way.
ContributeFrom A$5 a month · Cancel anytimeThe daily briefing
Start informed.
The essential headlines, the useful context and what to watch next, in your inbox each morning.







Comments
0 commentsCommunity rules
To read and join the conversation, please agree to our rules.
You have agreed to the community rules.
No comments yet. Start the conversation.